Pharmaceutical TechnologyOriginal article
Roche licenses Simcere’s B-cell-targeting tri-specific for $1.53bn
PartnershipB-cell-targeting tri-specific antibodyPositive
AI Analysis
Summary
Roche licensed Simcere's B-cell-targeting tri-specific antibody for $1.53 billion, targeting B-cell mediated and autoimmune diseases.
Outcome Details
$1.53 billion licensing deal
Importance:7/10
Sentiment:
0.70
licensingpartnershipB-cell targetingtri-specific antibodyautoimmuneacquisition
Related Companies
Read the original article
Published by Pharmaceutical Technology on September 2, 2026 3:06 PM